Ukko

Ukko is a biotechnology company focused on addressing food allergies and sensitivities through innovative immunotherapies.

Founded in 2016 and headquartered in Tel Aviv, Israel, with an office in Palo Alto, California, Ukko combines immunology, computational biology, and protein engineering to develop treatments for individuals suffering from food allergies and gluten-related disorders. The company utilizes an advanced computational protein design platform that employs artificial intelligence and machine learning. This technology allows Ukko to create modified allergens that retrain the immune system, develop safe proteins for consumption, and design mRNA delivery systems to mitigate severe allergic reactions. Ukko's product pipeline includes investigational therapeutics for peanut allergies and improved gluten for celiac patients, with plans to expand to other major allergens. Ukko primarily serves pharmaceutical companies, food industry partners, healthcare providers, and ultimately aims to improve the quality of life for millions affected by food allergies.